Mahrab Al Rahman’s Post

Currently, Russia imports a wide range of pharmaceutical goods from India, including generic drugs, active pharmaceutical ingredients (APIs), vaccines, and medical devices. Indian companies have established themselves as reliable suppliers, meeting the demand for essential medicines in the Russian market. What will be the dynamics of this sector in the coming year of 2025? Read in our new blog post ⤵️ #partner #businesspartner #partnerinrussia #businesswithrussia #russiaandindia #russianindiantrade #exportmarketing #marketing #newmarket #russianmarket #cismarket #export #exim #trade #CONSULTANT #service #import #exporters #exportimport #importexport #pharma #indianpharma

India's pharma exports to US surge 15% in 11 months of FY24 The pace of exports has more than doubled from the 6.18% growth in the same period of FY23, according to estimates by Pharmaceutical Export Promotion Council (Pharmexcil). #IndiaPharma | #FY24 | #PharmaceuticalExportPromotion | #PaceofExports | #Healthnews Read more:

https://lnkd.in/d2HK5xW7 India's pharmaceutical sector stands at a crossroads. The journey toward self-reliance in API production is critical, not only for the stability of the industry but also for ensuring that India remains the world's "pharmacy" in both good times and bad.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

India's pharma exports rise 10% to USD 27.9 bn in FY24 Experts have said that India's pharmaceutical business may exceed USD 130 billion by 2030, supported by expanding market opportunities and heightened demand in the overseas markets. The business stood at over USD 50 billion for the 2022-23. #IndiasPharmaExports | #IndiaPharmaceuticalBuisness | #Overseasmarket | #MarketOpportunities | #Healthnews Read more:

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

*Pakistan's Pharmaceutical Exports Soar: 31.11% Growth in Q1 2024-25!* Breaking News! Pakistan's pharmaceutical industry is making waves globally, recording a remarkable 31.11% increase in exports in the first quarter of FY 2024-25! Key Highlights: - $105.936 million in exports from July to September 2024, up from $80.796 million in 2023 - 61.55% year-on-year surge in September 2024, reaching $43.607 million - 53.78% month-on-month growth from August 2024 This impressive growth showcases Pakistan's expanding pharmaceutical capabilities and competitiveness on the global stage! *What's driving this success?* - Increased demand for quality generics - Growing international partnerships - Enhanced manufacturing capabilities - Government support for exports *Congratulations to Pakistan's pharmaceutical industry!* Let's discuss: - What opportunities arise from this growth? - How can we sustain this momentum? - What role can international collaborations play? Share your insights! #PharmaceuticalExports #Pakistan #EconomicGrowth #ExportIncrease #HealthcareIndustry #PBS #FinancialYear2024 #MadeInPakistan #GlobalMarket #PharmaInnovation #GrowthStory #IndustryNews #TradeNews #BusinessUpdate #MarketWatch #Trends2024 #BusinessInsights #HealthcareSector #PakistanEconomy #ExportLedGrowth #PharmaceuticalManufacturing

Indian Pharm Exports grows at 10.2%. In May 2024, India's pharmaceutical exports showed significant growth. The export value for drugs and pharmaceuticals increased by 7.36%, rising from USD 2.26 billion in April 2023 to USD 2.43 billion in April 2024. For the fiscal year 2023-24, the total pharmaceutical exports were projected to reach USD 28 billion, marking an incremental growth of 10.2% compared to the previous fiscal year. This growth was driven by increased demand in the United States and Europe due to critical drug shortages in this region. Growth highlights India's role as a key supplier of pharmaceuticals globally, despite facing challenges such as stringent regulatory requirements, supply chain disruptions, and quality control issues. The sector's expansion reflects both resilience and the capacity to address global health needs effectively.